Revance Therapeutics reported $72K in Ordinary Share Capital for its first fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ordinary Share Capital Change
Aerie Pharmaceuticals AERI:US $ 0.05M 0M
ALKERMES ALKS:US $ 1.69M 0.01M
Bristol Myers Squibb BMY:US $ 292M 0M
Cara Therapeutics CARA:US $ 53K 0
Coherus Biosciences CHRS:US $ 0.01M 0M
Eli Lilly And LLY:US $ 594.1M 0M
Endo International Ordinary Shares ENDP:US $ 0.07M 0M
Horizon Pharma HZNP:US $ 0.02M 0M
JAZZ PHA JAZZ:US $ 0.06M 0M
Neurocrine Biosciences NBIX:US $ 0.1M 0M
Pacira Pharmaceuticals PCRX:US $ 0.05M 0M
Revance Therapeutics RVNC:US $ 0.07M 0M
Supernus Pharmaceuticals SUPN:US $ 0.05M 0M
Teva Pharmaceutical Industries TEVA:US $ 57M 0M